Combined antiviral options for the treatment of chronic hepatitis C

Antiviral Research

Volumn 60, Issue 2, 2003, Pages 135-143

  Medina, Jesús ^a   García Buey, Luisa ^a   Moreno Monteagudo, José A ^a   Trapero Marugán, María ^a   Moreno Otero, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Antiviral therapy; Combination therapy; Hepatitis C; Interferon; Pegylated interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; BLOOD DISEASE; BODY WEIGHT; BRAIN DISEASE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DEPRESSION; DOSE RESPONSE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEALTH STATUS; HEMOLYSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY CLEARANCE; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MENTAL DISEASE; MOLECULAR WEIGHT; MONOTHERAPY; NEUTROPENIA; PATIENT CODING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECIPIENT; RELAPSE; SIDE EFFECT; TERATOGENICITY; TREATMENT OUTCOME; VIRUS LOAD;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 0344443223     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.08.009     Document Type: Conference Paper

References (71)

1. Alberti A., Benvegnù L. Management of hepatitis C. J. Hepatol. 38:2003;S104-S118.
2. Algranati N.E., Sy S., Modi M. A branched methoxy 40. kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of peginterferon alpha-2A and may explain its enhanced efficacy in chronic hepatitis C Hepatology. 30:1999;190.
3. Andreone P., Gramenzi A., Cursaro C., Sbolli G., Fiorino S., Giammarino L.D., Miniero R., D'Errico A., Gasbarrini G., Bernardi M. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial. J. Hepatol. 30:1999;788-793.
4. Anonymous., 1999. EASL International Consensus Conference on Hepatitis C. J. Hepatol. Suppl. 31, 3-8.
5. Bacon B. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology. 36:2002;S179-S184.
6. Barbaro G., Lorenzo G.D., Belloni G. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am. J. Med. 107:1999;112-118.
7. Barbaro G., Lorenzo G.D., Soldini M., Giancaspro G., Bellomo G., Belloni G., Grisorio B., Annese M., Bacca D., Francavilla R., Rizzo G., Barbarini G. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon alpha alone: an Italian multicenter, randomized, controlled, clinical study. Am. J. Gastroenterol. 93:1998;2445-2451.
8. Bell, H., Hellum, K., Harthug, S., Myrvang, B., Ritland, S., Maeland, A., Von der Lippe, B., Bjoro, K., Skaug, K., Gutigard, B., Raknerud, N., Simmonds, P., 1999. Treatment with interferon alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group. Scand. J. Gastroenterol. 34, 194-198.
9. Bellobuono A., Mondazzi L., Tempini S., Silini E., Vicari F., Ideo G. Ribavirin and interferon-alpha combination therapy vs. interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J. Viral Hepatitis. 4:1997;185-191.
10. Blight K.J., Kolykhalov A., Rice C. Efficient initiation of HCV RNA replication in cell culture. Science. 290:2000;1972-1974.
11. Bonkovsky H.L., Stefancyk D., Leclair P. Low doses (600. mg/day) of ribavirin are superior to high doses (1000-1200 mg/day) with interferon for chronic hepatitis C: results of a controlled, randomized, multicenter trial Hepatology. 30:1999;265.
12. Brillanti S., Garson J., Foli M., Whitby K., Deaville R., Masci C., Miglioli M., Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 107:1994;812-817.
13. Brillanti S., Miglioli M., Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J. Hepatol. 23:1995;13-15.
14. Casanovas-Taltavull T., Baliellas C., Benasco C., Serrano T., Casanova A., Perez J., Guerrero L., Gonzalez M., Andres E., Gil-Vernet S., Casais L. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am. J. Gastroenterol. 96:2001;1170-1177.
15. CDC, 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related disease. MMWR Recomm. Rep. 47, 1-40.
16. Cerny A., Chisari F. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology. 30:1999;595-601.
17. Cornberg M., Hadem J., Bastuerk M. Early HCV RNA decline during treatment with peginterferon alfa-2b plus ribavirin or conventional interferon alfa-2b plus ribavirin: analysis of 80 patients treated at a single center. Hepatology. 34:2001;217A.
18. Cummings K.J., Lee S., West E., Cid-Ruzafa J., Fein S., Aoki Y., Sulkowski M., Goodman S. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA. 285:2001;193-199.
19. Davis G.L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S., Trepo C., Shiffman M., Zeuzem S., Craxi A., Ling M., Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New Engl. J. Med. 339:1998;1493-1499.
20. Eyster M.E., Diamondstone L., Lien J., Ehmann W., Quan S., Goedert J. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. J. Acq. Imm. Def. Synd. 6:1993;602-610.
21. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpoldeer J., Strazzera A., Chien D., Munoz S., Balestrieri A., Purcell R.H., Alter H.J. The outcome of acute hepatitis C predicted by evolution of the viral quasisipecies. Science. 288:2000;339-344.
22. Ferenci P., Peck-Radosavljevic M., Vogel W. 40. kDa peginterferon alfa-2a (Pegasys) in post-liver transplant recipients with established recurrent hepatitis C: preliminary results of a randomized multicenter trial Hepatology. 34:2001;406A.
23. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology. 36:2002;S237-S244.
24. Fried M.W., Shiffman M., Reddy R., Smith C., Marinos G. Jr., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peg interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl. J. Med. 347:2002;975-982.
25. Garcia-Samaniego J., Soriano V., Castilla J., Bravo R., Moreno A., Carbo J., Iniguez A., Gonzalez J., Munoz F. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am. J. Gastroenterol. 92:1997;1130-1134.
26. Glue P., Fang J., Rouzier-Panis R. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 68:2000;556-567.
27. Hadziyannis S.J., Cheinquer H., Morgan T., Diago M., Jensen D., Sette H. Peginterferon alfa-2a (40. kDa) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomised, double-blind multicentre study examining effect of duration of treatment and RBV dose J. Hepatol. 36:2002;3.
28. Halprin A., Trotter J., Everson G. Post-transplant eradication of hepatitis C by pre-transplant treatment in living donor liver transplant recipients. Hepatology. 34:2001;244A.
29. Heathcote E.J., Shiffman M., Cooksley W., Dusheiko G., Lee S., Balart L., Reindollar R., Reddy R., Wright T., Lin A., Hoffman J., De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New Engl. J. Med. 343:2000;1673-1680.
30. Hoofnagle J.H., Bisceglie A.D. The treatment of chronic viral hepatitis. New Engl. J. Med. 336:1997;347-356.
31. Jacobsen I. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy nonresponders. Gastroenterology. 122:2002;A626.
32. Jonas M. Children with hepatitis C. Hepatology. 36:2002;S173-S178.
33. Landau A., Batisse D., Huyen J.V., Piketty C., Bloch F., Pialoux G., Belec L., Petite J., Weiss L., Kazatchkine M. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS. 14:2000;839-844.
34. Liang T.J., Rehermann B., Seeff L., Hoofnagle J. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132:2000;296-305.
35. Lindsay K.L., Trepo C., Heintges T., Shiffman M., Gordon S., Hoefs J., Schiff E., Goodman Z., Laughlin M., Yao R., Albrecht J. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 34:2001;395-403.
36. Lohmann V., Korner F., Koch J., Herian U., Theilmann L., Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 285:1999;110-113.
37. Major M., Feinstone S. The molecular biology of hepatitis C. Hepatology. 25:1997;1527-1538.
38. Manns M.P., McHutchison J., Gordon S., Rustgi V., Shiffman M., Reindollar R., Goodman Z., Koury K., Ling M., Albrecht J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965.
39. Manzarbeitia C., Tepermann L., Chalasani N. 40. kDa peginterferon alfa-2a (Pegasys) as a prophylaxis against hepatitis C infection recurrence after liver transplantation (LT): preliminary results of a randomized multicenter trial Hepatology. 34:2001;406A.
40. Marcellin P., Pouteau M., Martinot-Peignoux M., Degos F., Duchatelle V., Boyer N., Lemonnier C., Degott C., Erlinger S., Benhamou J. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology. 109:1995;156-165.
41. McHutchison J.G., Gordon S., Schiff E., Shiffman M., Lee W., Rustgi V., Goodman Z., Ling M., Cort S., Albrecht J. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl. J. Med. 339:1998;1485-1492.
42. Milella M., Santantonio T., Pietromatera G., Maselli R., Casalino C., Mariano N., Genchi C., Pastore G. Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone. Italian J. Gastroenterol. Hepatol. 31:1999;211-215.
43. Modi M., Fulton J., Buckmann D., Wright T., Moore D. Clearance of pegylated (40. kDa) interferon alfa-2a(Pegasys) is primarily hepatic Hepatology. 32:2000;371A.
44. Moreno-Monteagudo J.A., Castro A., Pedro A.D., Lorenzo J., Fernandez-Bermejo M., Lopez S., Garcia-Buey L., Borque M., Pedreira J., Moreno-Otero R. Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers. Aliment. Pharmacol. Ther. 16:2002;243-249.
45. Moreno-Otero R., García-Buey L., Mateos F., García- Monzón C. Pathogenesis of chronic viral hepatitis: lessons from immunohistochemistry. Viral Hepatitis Rev. 2:1996;61-79.
46. Nieforth K.A., Nadeau R., Patel I., Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin. Pharmacol. Ther. 59:1996;636-646.
47. NIH, 2002. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 36, S3-S20.
48. Perlemuter G., Sabile A., Letteron P., Vona G., Topilco A., Chretien Y., Koike K., Pessayre D., Chapman J., Barba G., Brechot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis:a model of vital-related steatosis. FASEB J. 16:2002;185-194.
49. Pol S., Couzigou P., Bourliere M., Abergel A., Combis J., Larrey D., Tran A., Moussalli J., Poupon R., Berthelot P., Brechot C. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. J. Hepatol. 31:1999;1-7.
50. Poynard T., Leroy V., Cohard M., Thevenot T., Mathurin P., Opolon P., Zarski J. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 24:1996;778-789.
51. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 349:1997;825-832.
52. Poynard T., Marcellin P., Lee S., Niederau C., Minuk G., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
53. Reddy K.R., Wright T., Pockros P., Shiffman M., Everson G., Reindollar R., Fried M., Purdum P.P. Jr., Jensen D., Smith C., Lee W.M., Boyer T.D., Lin A., Pedder S., DePamphilis J. Efficacy and safety of pegylated (40-kDa) interferon [alpha]-2a compared with interferon [alpha]-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 33:2001;433-438.
54. Reichard O., Norkrans G., Fryden A., Braconier J., Sonnerborg A., Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet. 351:1998;83-87.
55. Ruggieri A., Harada T., Matsuura Y., Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology. 229:1997;68-76.
56. Samuel D., Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J. Viral Hepatitis. 7:2000;87-92.
57. Sanchez-Quijano A., Andreu J., Gavilan F., Luque F., Abad M., Soto B., Munoz J., Aznar J., Leal M., Lissen E. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur. J. Clin. Microbiol. Infect. Dis. 14:1995;949-953.
58. Scotto G., Fazio V., Tantimonaco G. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J. Gastroenterol. 28:1996;505-511.
59. Sherman M., Marinos G., Sedarati F. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann. Intern. Med. 135:2001;927-928.
60. Shiffman M. Retreatment of interferon and interferon-ribavirin non-responders with peginterferon alpha-2a and ribavirin: initial results from the lead-phase of the HALT-C. Hepatology. 34:2001;243A.
61. Shiffman M. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long term treatment against cirrhosis (HALT-C) trial [abstract]. Hepatology. 36:2002;295A.
62. Soriano V., Sulkowski M., Bergin C., Hatzakis A., Cacoub P., Katlama C., Cargnel A., Mauss S., Dieterich D., Moreno S., Ferrari C., Poynard T., Rockstroh J. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS. 16:2002;813-828.
63. Sostegni R., Ghisetti V., Pittaluga F., Marchiaro G., Rocca G., Borghesio E., Rizzetto M., Saracco G. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial. Hepatology. 28:1998;341-346.
64. Sulkowski M.S., Thomas D., Chaisson R., Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 283:2000;74-80.
65. Takano S., Yokosuka O., Imazeki F., Tagawa M., Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 21:1995;650-655.
66. Tan, S.L., Katze, M., 2001. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology, 1-12.
67. Wills R.J. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet. 19:1990;390-399.
68. Wirth S., Lang T., Gehring S., Gerner P. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 36:2002;1280-1284.
69. Xu Z.X., Patel I., Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon alfa-2a (IFN alfa-2a) to healthy subjects. Hepatology. 28:1998;702.
70. Zeuzem S., Feinman S., Rasenack J., Heathcote E., Lai M., Gane E., O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., Brunda M.J. Peginterferon alfa-2a in patients with chronic hepatitis C. New Engl. J. Med. 343:2000;1666-1672.
71. Zylberberg H., Benhamou Y., Lagneaux J., Landau A., Chaix M., Fontaine H., Bochet M., Poynard T., Katlama C., Pialoux G., Brechot C., Pol S. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut. 47:2000;694-697.